Welcome to the spring edition of US Neurology!
We are proud to have active support from our media partners and editorial board members and this edition features many contributions from them, including an interview with Dr Martin Farlow discussing the concept of preclinical Alzheimer’s disease and the DIAN-TU trial and a selection of interviews conducted at the American Epilepsy Society Meeting in November 2018, which highlight some of the hottest topics in the field. Rosalind Kalb et al. present a special report on the National MS Society’s MS Navigator® Service, which aims to facilitate greater patient independence and quality of life.
This edition also includes many more from leading experts in the fields of Parkinsons’ disease, multiple sclerosis, neuromuscular diseases and a supplement that features highlights of a spotlight debate on the potential for the antipsychotic agent pimavanserin to increase mortality among patients with Parkinson’s disease psychosis.
US Neurology would like to thank everyone who contributed towards this issue. We trust that you will find it an informative read.
Enjoy and happy reading!
Foreword – US Neurology. 2019;15(1):9
Welcome to the spring edition of US Neurology. This journal aims to address topical subjects in the field of neurology to stimulate discussion focused on these issues. Articles have been chosen for their evaluation of current practices and research and their discussion of future innovations that directly affect neurologists and other practitioners involved in the care […]
Latest Developments in Preclinical Alzheimer’s Disease
In the last decade, our understanding of Alzheimer’s disease has advanced considerably. Thanks to evolving biomarker research, it is now recognized that a preclinical stage occurs before the occurrence of symptoms.1 This preclinical phase has become the focus of considerable research efforts as early intervention is likely to offer the best chances of a cure. […]
Molecular Pathogenesis of Alzheimer’s Disease
Alzheimer’s disease was first described in 1906, and yet we have still not fully elucidated the pathogenesis of the condition. It is known that the disease is characterized by the polymerization of amyloid β-peptide (Aβ), leading to the formation of plaques.1,2 The cascade of events initiated by Aβ polymerization eventually leads to progressive neurodegeneration and […]
Imaging, Technology, and Parkinson’s Disease
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopamine production in the substantia nigra. While oral therapies can effectively augment the dopaminergic pathway, their effect lessens as the disease progresses, and patients require multiple adjustments to their medication regimen. Neuromodulation using deep brain stimulation (DBS) is a powerful tool to […]
Hot Topics in Epilepsy — Highlights of the American Epilepsy Society Annual Meeting 2018
The American Epilepsy Society Annual Meeting is the largest gathering on epilepsy in the world. The 2018 meeting, which was held in New Orleans, Louisiana, from November 30–December 4, 2018, featured symposia, workshops, and lectures aimed at healthcare practitioners involved in all aspects of the care of patients with epilepsy. In a number of expert […]
Case Management Services to Meet the Complex Needs of Patients with Multiple Sclerosis in the Community—The Successes and Challenges of a Unique Program from the National Multiple Sclerosis Society
Multiple sclerosis (MS) is a chronic, unpredictable disease for which we do not yet have a cure or fully effective treatment.1 The available disease-modifying therapies reduce inflammatory activity and progression of disability for many people. However, some individuals experience physical, cognitive, and/or emotional changes over the disease course that severely compromise function, independence, safety, participation, and […]
Existing and Emerging Approaches to Treating Chronic Inflammatory Demyelinating Polyneuropathy
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated disorder of the peripheral nervous system, of unknown etiology.1 The condition usually presents as weakness in the arms and legs, balance/gait impairment, tingling, numbness, and loss of tendon reflexes.2–4 It can be relapsing or progressive and the available treatments have variable efficacy in different patients.5,6 The symptoms of CIDP cause […]
Challenges of Interpreting Dystrophin Content by Western Blot
Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene that disrupt the production of functional dystrophin protein, resulting in progressive muscle damage and loss of contractile function. Currently, multiple therapeutic agents that aim to restore dystrophin expression are being evaluated in clinical trials (clinicaltrials.gov identifiers: NCT02310906, NCT02740972, NCT03368742, NCT03508947, NCT03769116, and NCT03362502). […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!